Sagemcom SICONIA™ Software Suite Selected by Groupe E for Its Smart Meter Deployment in Switzerland
19.4.2022 15:15:00 EEST | Business Wire | Press release
On March 7th of 2022, Sagemcom has been selected by Groupe E for the delivery of its SICONIA ™ Software suite composed of:
- A “Multi-energy and scalable Head-End System (HES)”, embedding a Hardware Security Module (HSM) based Key Management System (KMS) complying will state-of-the art industry security standards, and with all swiss and Groupe E security requirements;
- A “Big data-based Meter Data Management system (MDMS)” including analytics, Business Intelligence and advanced integration capabilities with Groupe E IS ecosystem including SAP.
“Digital solutions make it possible, to collect, process and enhance metering data in increasingly complex grids” said Mr. Eric RIEUL, CEO of Sagemcom Energy & Telecom. “As a mission-driven company, Sagemcom is fully committed for a clean and sustainable energy transition. Sharing these values together, we are very proud to support Groupe E by providing our End-to-End smart metering solution. This large-scale project is the beginning of the Smart Grid journey in Switzerland and a long-term partnership with Groupe E”.
In addition to the meter-to-cash services, Sagemcom’s SICONIA ™ Software Suite (HES, MDMS) will allow Groupe E to take a step forward and enable a large set of smart grid services and use cases such as the management of distributed energy resources (Renewable energy resources, Electric Vehicles charging points, etc.), the improvement of flexibility services, the management of individual and grouped self-consumption, the improvement of the Quality of Supply and other grid oriented services. With the digitization of the low-voltage network, Sagemcom and Groupe E aim to further enhance grid management with analytics capabilities.
"The deployment of smart meters represents a key step in the decarbonization process. In this sense, we are convinced that Sagemcom is the best partner to help us carry out our mission and accompany our customers in their energy transition", said Mr. Jacques MAURON, CEO of Groupe E.
As part of Sagemcom’s managed services offer, the solution will be delivered to Groupe E in SaaS (Software as a Service) mode, as Sagemcom will take care of the IT hosting and monitoring, security management, and support and maintenance services to allow Groupe E to focus on the business operations of the solution.
This project will last at least 8 years and will cover Groupe E service areas in the canton of Fribourg, Vaud and Neuchâtel.
About Sagemcom
Thanks to the innovative solutions designed and built by our people, Sagemcom provides access to broadband Internet, entertainment and managed energy supply to the greatest number all over the world.
As a “mission-driven company” since January 2022, Sagemcom makes sure that the design, construction and use of these solutions are sustainable, and fulfil the environmental and societal commitments that are known and shared by all our employees, partners and stakeholders.
In LBO since its 2008 carve-out with Safran, Sagemcom group entered its fourth LBO in 2019, with Charterhouse as the majority shareholder. Sagemcom is 30% owned by its employees, achieves over €2.2 billion turnover, is world leader in its markets, has been profitable since it was founded, and has been growing continuously since 2016.
www.sagemcom.com // https://www.linkedin.com/company/sagemcom // www.facebook.com/SagemcomOfficial // https://twitter.com/Sagemcom // https://www.instagram.com/sagemcom_inside
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005613/en/
Contact information
Media Contact
Sylvaine COULEUR (presse@sagemcom.com)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom